Slide 1: Fourth Quarter Fiscal 2024 Earnings Call
Cencora, Inc. Fourth Quarter Fiscal 2024 Earnings Call November 6, 2024
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: Cencora long-term vision and targeted EPS growth
8% - 12%* targeted long-term adjusted diluted EPS growth Cencora is united in our *Growth rates given on a constant currency basis responsibility to create healthier futures. Long-term vision of Cencora creates unparalleled expanding leadership and access, efficiency, and reliability for growing hig
Slide 4: Fiscal 2024 highlights & strategic overview
Fiscal 2024 highlights & strategic overview Business highlights Financial highlights Fiscal 2025 guidance • Cencora announced that it has entered • Introduced fiscal 2025 guidance, into a definitive agreement to acquire reflecting adjusted operating income Retina Consultants of America $13.76 growth
Slide 5: Strategic acquisition of Retina Consultants of America (RCA)
Strategic acquisition of Retina Consultants of America (RCA) Acquisition of RCA expected to: • Broaden our relationships with community providers in a high growth segment • Continue the natural evolution of our leadership in Specialty into MSO for key community provider customer base • Provide our c
Slide 6: Financial results
cencord Financial results
Slide 7: Q4 fiscal 2024 financial summary
Q4 fiscal 2024 Consolidated results GAAP Adjusted (non-GAAP)(1) financial summary Revenue y/y% $79.1B 14.7% $79.1B 14.7% 14.7% Gross profit $2.5B $2.5B Revenue growth y/y y/y% 10.6% 6.6% 6.3% Operating expenses $2.4B $1.6B Consolidated y/y% 33.2% 6.8% adjusted operating income(1) growth y/y Operatin
Slide 8: U.S. Healthcare Solutions segment
U.S. Healthcare Solutions segment Q4 fiscal 2024 financial results Financial results Q4 Q4 y/y% fiscal 2024 fiscal 2023 • Revenue increased 15.7% to $71.7B due to overall market growth primarily driven Revenue $71.7B $61.9B 15.7% by unit volume growth, including increased sales of products labeled f
Slide 9: International Healthcare Solutions segment
International Healthcare Solutions segment Q4 fiscal 2024 financial results Constant Financial results Q4 Q4 y/y% currency(1) (as reported) fiscal 2024 fiscal 2023 • Revenue increased 5.5% to $7.4B on an y/y% as-reported basis. On a constant $7.4B $7.0B 5.5% 7.9% currency basis, revenue increased Re
Slide 10: Fiscal 2024 financial summary
Fiscal 2024 Consolidated results GAAP Adjusted (non-GAAP)(1) financial summary Revenue y/y% $294.0B 12.1% $294.0B 12.1% 12.1% $9.9B $9.7B Revenue growth y/y Gross profit y/y% 10.6% 8.1% 10.9% Consolidated Operating expenses $7.7B $6.1B y/y% 16.9% 6.5% adjusted operating income(1) growth y/y Operatin
Slide 11: Fiscal 2025 guidance
cencord Fiscal 2025 guidance
Slide 12: Fiscal 2025 guidance
Fiscal 2025 guidance As reported Constant currency(2) Consolidated Revenue 7% to 9% Adjusted operating income(1) 5% to 6.5% U.S. Healthcare Solutions Revenue 7% to 9% Operating income 5% to 6.5% International Healthcare Solutions Revenue 7% to 9% 7% to 9% Operating income 5% to 6.5% 5% to 6.5% 1 The
Slide 13: Fiscal 2025 guidance continued
Fiscal 2025 guidance continued Fiscal 2025 Guidance Fiscal 2024 Actual Adjusted diluted earnings per share(1) $14.80 to $15.10 $13.76 Net interest expense $150 to $170 million $157 million Adjusted effective tax rate (1) ~21% 20.8% Diluted weighted average shares outstanding ~196 million 200.3 milli
Slide 14: Advancing environmental, social, and governance
Environmental Adapting to a changing climate • Near-term Science-Based Target validated by the Science Based Targets initiative • Established business resiliency planning target by completing business impact and climate risk assessments across locations • Completed several on-site renewable energy p
Slide 15: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Our 5 Strategic Imperatives Why we exist We are united in our responsibility to create healthier futures Advance core business Enhance capa
Slide 16: Appendix
cencord Appendix
Slide 17: GAAP to non-GAAP reconciliations (Q4 2024)
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended September 30, 2024 Net Income Diluted Operating Income Before Income Tax Attributable Earnings Gross Profit Expenses Operating Income Income Taxes Expense to Cencora Per Share GAAP $ 2
Slide 18: GAAP to non-GAAP reconciliations (Q4 2023)
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended September 30, 2023 Net Income Diluted Operating Income Before Income Tax Attributable Earnings Gross Profit Expenses Operating Income Income Taxes Expense to Cencora Per Share GAAP $ 2
Slide 19: GAAP to non-GAAP reconciliations (FY 2024)
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Fiscal Year Ended September 30, 2024 Net Income Diluted Operating Income Before Income Tax Attributable to Earnings Gross Profit Expenses Operating Income Income Taxes Expense Cencora Per Share GAAP $ 9,
Slide 20: GAAP to non-GAAP reconciliations (FY 2023)
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Fiscal Year Ended September 30, 2023 Net Income Diluted Attributable to Net Income Operating Income Before Income Tax Noncontrolling Attributable Earnings Gross Profit Expenses Operating Income Income Ta
Slide 21: Supplemental information regarding non-GAAP financial measures
Supplemental information regarding non-GAAP financial measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 22: Supplemental information regarding non-GAAP financial measures (cont.)
Supplemental information regarding non-GAAP financial measures (cont.) • Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling interest excludes the non-controlling interest portion of the same items described above. Management beli
Slide 23: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations & Treasury bennett.murphy@cencora.com